The most common question we receive about SKNCODE™ is some version of: "How is this different from a skin quiz?"
It is a reasonable question. The landscape of digital skin assessment has produced many tools that present a series of questions — skin type, concern, age, lifestyle — and return a product recommendation. The experience feels personalised. The underlying logic is not.
SKNCODE™ is built on a fundamentally different premise: that visible skin concerns are downstream signals, and that the most useful thing a platform can do is identify what is driving them — not simply match them to a product category.
Here is how that works in practice.
The Signal Layer: What the AI Reads
The platform begins with an AI facial analysis — a 60-second image-based assessment that identifies and scores five concern categories: wrinkles and laxity, pigmentation and uneven tone, redness and sensitivity, dark circles, and eye bags.
This is the signal layer. What the AI is reading is not simply the presence of these concerns — it is their pattern, distribution, and relative severity. A wrinkle in the glabellar region (between the brows) tells a different biological story than one in the periorbital region. Periorbital pigmentation involving the tear trough has a different likely mechanism than malar pigmentation on the cheekbone. The distribution encodes information about likely drivers.
The output of the AI assessment is not a product recommendation. It is a biological signal map — identifying where to look, and what questions to ask next.
The Genetic Layer: What Your DNA Tells Us
For individuals who want greater precision, SKNCODE™ integrates at-home genetic testing through an approved laboratory partner. The genetic profile identifies constitutional vulnerabilities — fixed biological tendencies that cannot be changed, but can and should be accommodated in the protocol.
The key variants assessed include MC1R polymorphisms (which determine pigmentation response and UV sensitivity), collagen synthesis gene variants (which influence the rate of ECM maintenance and repair), inflammatory response genes (which predict tendency toward redness, sensitivity, and post-inflammatory pigmentation), and antioxidant pathway variants (which influence how efficiently the skin neutralises Reactive Oxygen Species (ROS)).
This information reframes the visible concern. A person with an MC1R variant that increases pigmentation risk is not simply someone who "gets dark spots easily." They have a specific molecular reason for that tendency — one that points toward a specific intervention target at the Melanocyte Inducing Transcription Factor (MITF) level, not simply a general instruction to avoid sun exposure.
The Biomarker Layer: What the Blood Reveals
For individuals entering the most targeted tier of the platform — or those whose skin concerns have a clear systemic component — biomarker testing provides the third data stream.
Inflammatory markers, hormonal panels, and targeted metabolic biomarkers connect what is happening on the surface to what is happening systemically. Elevated high-sensitivity C-Reactive Protein (hs-CRP) suggests chronic systemic inflammation that will consistently undermine skin repair. Hormonal imbalances explain pigmentation that returns despite topical treatment. Oxidative stress markers indicate that the antioxidant arm of a protocol needs to be significantly more robust than a standard formulation provides.
Biomarker data does not replace the clinical assessment or the AI analysis. It contextualises them. It answers the question: what is driving what I am seeing, at the level of the whole body — not just the skin?
The Protocol: What Follows the Data
A SKNCODE™ precision protocol is built from five modalities: medical-grade topical skincare, nutritional supplements, in-clinic treatments, at-home devices, and lifestyle optimisation. Every recommendation within each modality is matched to a specific biological driver identified through the assessment layers above.
A protocol for melanogenesis dysregulation in a person with an identified MC1R variant looks different from a protocol for the same visible presentation in a person without that variant. A protocol for redness driven by TLR2 overactivation looks different from one addressing redness driven by barrier dysfunction. The visible concern may appear similar. The biology is not.
This is the fundamental distinction between precision and approximation. The platform does not produce a better version of a generalised protocol. It produces a protocol that is, as specifically as current science allows, calibrated to the actual biological drivers of one individual's skin.